TP53 and neoplasm: In a study designed to monitor response to neoadjuvant chemotherapy (NCT) and detect minimal residual disease after surgery, Francesca Riva, et al. used customized droplet digital PCR (ddPCR) assays to track tumor protein p53 (TP53) mutations previously characterized in tumor tissue by massively parallel sequencing.